Latest Content

October brought updates in the lung cancer field, ranging from notable trial results to patient perspectives on navigating treatment and survivorship.

Steve Brown and Lisa Booth sat down for a joint interview with CURE to discuss the future of patient-driven artificial intelligence in cancer care.

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma.

Jeannine Walston, who has contributed to CURE since 2015, was diagnosed with a brain tumor in March 1998.

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape genitourinary cancer care.

More than a quarter of tested patients with non-small cell lung cancer responded to Amtagvi monotherapy.

Specialized sarcoma centers enhance coordinated care for young adults, although travel and financial barriers persist, Dr. Vinayak Venkataraman stated.

This year’s Breast Cancer Awareness Month highlighted FDA approvals, survivorship challenges and advances in breast reconstruction.

‘Coping With Cancer in Early Adulthood’ addresses issues of patients 18 to 49 years old.

CURE attended the Hairy Cell Leukemia Foundation 2025 Conference where medical experts gathered to discuss advances in research and patient care.

A young cancer survivor who underwent external beam radiation therapy and brachytherapy at 14 years old discusses her rare diagnosis, side effects and the nonlink to her Turner syndrome.

The U.S. FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.